Hydroxyurea, a potential new anti-HIV agent. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Hydroxyurea, a potential new anti-HIV agent. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Treat Issues. 1995 Jan;9(1):7-9. Unique Identifier : AIDSLINE AIDS/95700116
Torres G

Abstract: Published evidence from the U.S. and Europe supports the effect of the anticancer drug hydroxyurea against HIV-1, and its potential synergistic effect with ddl. Approved as an oral chemotherapeutic agent for leukemia and other cancers, hydroxyurea acts as a radical free quencher, inhibiting the cellular enzyme ribonucleotide reductase as well as cellular DNA synthesis during the S phase of the cell division, and it may be through this mechanism that hydroxyurea inhibits tumor cell growth. French scientists at the Centre Leon Bernard in Lyon tested hydroxyurea and a related compound, D-aspartic acid beta-hydroxamate alone and in combination with AZT, ddl, or ddC. Total suppression of viral production and total production against the toxic effects induced by viral replication were demonstrated using the combination of either of the two hydroxamates and ddl after 14 days. In test tube experiments conducted at the National Cancer Institute, both hydroxyurea and ddl inhibited or delayed HIV replication in a dose-dependent manner; in combination, they blocked HIV replication by more than 99.9 percent.

Keywords: Didanosine/THERAPEUTIC USE Drug Therapy, Combination DNA Replication/*DRUG EFFECTS Human Hydroxyurea/*PHARMACOLOGY/THERAPEUTIC USE HIV/PHYSIOLOGY HIV Infections/*DRUG THERAPY Leukocytes, Mononuclear/DRUG EFFECTS/VIROLOGY Virus Replication/*DRUG EFFECTS Zalcitabine/THERAPEUTIC USE Zidovudine/THERAPEUTIC USE NEWSLETTER ARTICLE REVIEW
950530
M9551023

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .